Schering aquires CIS bio international
Berlin, Germany, January 3, 2002; Schering AG, Germany, has acquired the remaining 40 percent of CIS bio international S.A. (CIS) from Areva S.A., France. This transaction complements Schering AG’s 60 percent ownership interest in CIS, which was acquired in 2000. Schering AG now wholly owns the company.
CIS specialises in the development, production, marketing and distribution of radiopharmaceuticals for diagnosis and therapy. CIS also has a strong portofolio and reputation in the in-vitro diagnostic field, radioimmunology and Drug screening.
"The acquisition and integration of CIS into Schering AG's worldwide activities supports Schering AG's strategy to become a substantial player in the global radiopharmaceutical market," said Hans-Michael Rook, Head of Diagnostics and Radiopharmaceuticals at Schering AG. "The area of oncological radiopharmaceuticals presents a particularly attractive opportunity given Schering AG's existing expertise in oncology and the potential for synergies between its diagnostics and therapeutics businesses".
Other news from the department business & finance
